GRIN Therapeutics

GRIN Therapeutics Focuses on Researching and Developing Precision Therapies for Neurodevelopmental Disorders in Children, Aiming to Bring Hope to Patients and Caregivers. At the End of Last Year, GRIN Therapeutics Reported Promising Topline Data from a Phase 1b/2a Clinical Trial (Honeycomb Trial, ClinicalTrials.gov NCT Identifier: NCT05818943), Which Assessed the Efficacy of Radiprodil in GRIN-Related Neurodevelopmental Disorders (GRIN-NDD) in Gain-of-Function (GoF) Variant Patients, Leading to the Decision to Advance to a Global Phase 3 Trial. The Company Also Has an Ongoing Clinical Trial to Evaluate the Potential of Radiprodil in Treating Tuberous Sclerosis Complex (TSC) and Type II Focal Cortical Dysplasia (FCD).